Epidemiology and cost of heart failure in children

Cardiology in the Young

Volumn 25, Issue 8, 2015, Pages 1460-1468

  Nandi, Deipanjan ^a   Rossano, Joseph W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

cardiomyopathy; costs; epidemiology; Heart failure; outcomes; value

Indexed keywords

ARTICLE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; EXTRACORPOREAL OXYGENATION; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; KIDNEY FAILURE; MEDICAL CARE; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESPIRATORY FAILURE; RESTRICTIVE CARDIOMYOPATHY; RISK FACTOR; VENTRICULAR ASSIST DEVICE; AMBULATORY CARE; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CASE REPORT; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; FEMALE; HEART DEFECTS, CONGENITAL; INFANT; UNITED STATES;

AMBULATORY CARE; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HEART DEFECTS, CONGENITAL; HEART FAILURE; HOSPITALIZATION; HUMANS; INFANT; UNITED STATES;

EID: 84961912457     PISSN: 10479511     EISSN: 14671107     Source Type: Journal    
DOI: 10.1017/S1047951115002280     Document Type: Article

References (44)

1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: e240-e327.
2. Law SP, Kim JJ, Decker JA, et al. Hospital charges for pediatric heart transplant hospitalizations in the United States from 1997 to 2006. J Heart Lung Transplant 2012; 31: 485-491.
3. Dayton JD, Kanter KR, Vincent RN, Mahle WT. Costeffectiveness of pediatric heart transplantation. J Heart Lung Transplant 2006; 25: 409-415.
4. O'Connor MJ, Rossano JW. Ventricular assist devices in children. Curr Opin Cardiol 2014; 29: 113-121.
5. Rossano JW, Kim JJ, Decker JA, et al. Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study. J Card Fail 2012; 18: 459-470.
6. Nandi D, Lin K, O'Connor M, et al. Hospital Charges for Pediatric Heart Failure Related Hospitalization Admissions in the United States from 2000 to 2009. In Press, Pediatric Cardiology, 2015.
7. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015; 131: e29-e322.
8. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013; 6: 606-619.
9. Frankel DS, Vasan RS, D'Agostino RB, et al. Resistin, adiponectin, and risk of heart failure. J Am Coll Cardiol 2009; 53: 754-762.
10. Damasceno A, Mayosi BM, Sani M, et al. The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med 2012; 172: 1386-1394.
11. Rossano JW, Shaddy RE. Heart failure in children: etiology and treatment. J Pediatr 2014; 165: 228-233.
12. Massin MM, Astadicko I, Dessy H. Epidemiology of heart failure in a tertiary pediatric center. Clin Cardiol 2008; 31: 388-391.
13. Rossano JW, Goldberg DJ, Mott AR, et al. The burden of heart failure related hospitalizations in children with single ventricle heart disease in the United States (abstract). Circulation 2012; 126 (Suppl 21): A11975.
14. Lipshultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003; 348: 1647-1655.
15. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003; 348: 1639-1646.
16. Andrews RE, Fenton MJ, Ridout DA, Burch M, British Congenital Cardiac Association. New-onset heart failure due to heart muscle disease in childhood: a prospective study in the United Kingdom and Ireland. Circulation 2008; 117: 79-84.
17. Wilkinson JD, Landy DC, Colan SD, et al. The pediatric cardiomyopathy registry and heart failure: key results from the first 15 Years. Heart Fail Clin 2010; 6: 401-413.
18. Tsirka AE, Trinkaus K, Chen SC, et al. Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol 2004; 44: 391-397.
19. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 42: 1687-1713.
20. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115: 773-781.
21. Webber SA, Lipshultz SE, Sleeper LA, et al. Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the Pediatric Cardiomyopathy Registry. Circulation 2012; 126: 1237-1244.
22. Wouters KA, Kremer LCM, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-578.
23. Wittlieb-Weber CA, Lin KY, Zaoutis TE, et al. Pediatric versus adult cardiomyopathy and heart failure-related hospitalizations: a value-based analysis. J Card Fail 2015; 21: 76-82.
24. Dipchand AI, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric heart transplantation report-2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33: 985-995.
25. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 2006; 296: 1867-1876.
26. Alexander PMA, Daubeney PEF, Nugent AW, et al. Long-term outcomes of dilated cardiomyopathy diagnosed during childhood: results from a national population-based study of childhood cardiomyopathy. Circulation 2013; 128: 2039-2046.
27. Pahl E, Sleeper LA, Canter CE, et al. Incidence of and risk factors for sudden cardiac death in children with dilated cardiomyopathy. J Am Coll Cardiol 2012; 59: 607-615.
28. Bharucha T, Lee KJ, Daubeney PEF, et al. Sudden death in childhood cardiomyopathy. J Am Coll Cardiol 2015; 65: 2302-2310.
29. Everitt MD, Sleeper LA, Lu M, et al. Recovery of echocardiographic function in children with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2014; 63: 1405-1413.
30. Shaddy RE, Boucek MM, Hsu DT, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007; 298: 1171-1179.
31. Daubeney PE, Nugent AW, Chondros P, et al. Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study. Circulation 2006; 114: 2671-2678.
32. O'Sullivan JJ, Roche SL, Crossland DS, Chaudhari MP, Kirk RC, Asif H. Recovery of heart function in children with acute severe heart failure. Transplantation 2008; 85: 975-979.
33. Lipshultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 2013; 382: 1889-1897.
34. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000; 102: 858-864.
35. Grupper A, Park SJ, Pereira NL, et al. Role of ventricular assist therapy for patients with heart failure and restrictive physiology: improving outcomes for a lethal disease. J Heart Lung Transplant 2015; 34: 1042-1049.
36. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy-a heart failure society of America practice guideline. J Card Fail 2009; 15: 83-97.
37. Mahle WT, Ianucci G, Vincent RN, Kanter KR. Costs associated with ventricular assist device use in children. Ann Thorac Surg 2008; 86: 1592-1597.
38. Mahle WT, Forbess JM, Kirshbom PM, Cuadrado AR, Simsic JM, Kanter KR. Cost-utility analysis of salvage cardiac extracorporeal membrane oxygenation in children. J Thorac Cardiovasc Surg 2005; 129: 1084-1090.
39. Feingold B, Arora G, Webber SA, Smith KJ. Cost-effectiveness of implantable cardioverter-defibrillators in children with dilated cardiomyopathy. J Card Fail 2010; 16: 734-741.
40. Porter ME. What is value in health care? N Engl J Med 2010; 363: 2477-2481.
41. Linking Quality to Payment. Retrieved June 16, 2015, from http://www.medicare.gov/hospitalcompare/linking-quality-to-payment.htmlAspxAutoDetectCookieSupport=1.
42. Drucker NA, Colan SD, Lewis AB, et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-257.
43. Isogai T, Yasunaga H, Matsui H, Tanaka H, Horiguchi H, Fushimi K. Effect of intravenous immunoglobulin for fulminant myocarditis on in-hospital mortality: propensity score analyses. J Card Fail 2015; 21: 391-397.
44. Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med 2013; 14: 686-693.